Publications by authors named "Jose Carlos Estevez Maria"
In order to characterize the real-world effectiveness and safety of perampanel during clinical use in Europe, we conducted a structured literature search and scoping review of real-world studies conducted in Europe in adolescents (aged ≥ 12 years) or adults who were prescribed perampanel for focal epilepsy or primary generalized tonic-clonic seizures in the context of idiopathic generalized epilepsy, published between January 2016 and July 2021. We identified 29 relevant studies (20 retrospective and 9 prospective) in 3608 patients; median study duration was 12 months. Most patients (76.
View Article and Find Full Text PDFArticle Synopsis
- Neurologic impairment can last for months after severe COVID-19 infection due to ongoing inflammation.
- A study analyzed cognitive functions in 152 patients recovering from severe SARS-CoV-2 infection, finding significant issues with memory, executive functions, and attention, alongside elevated anxiety and depression rates.
- The study also identified increased levels of certain plasma biomarkers in these patients, raising concerns about potential long-term cognitive effects or the risk of neurodegenerative diseases.
Article Synopsis
- The study aimed to explore how self-reported sleep quality affects cognitive function, anxiety, depression, and quality of life in patients with epilepsy (PWE) receiving anti-seizure medications.
- Researchers included a sample of 150 patients, who completed various assessments, revealing that 44.4% experienced poor sleep quality and many showed signs of mild cognitive impairment.
- While sleep quality didn't independently predict cognitive issues, poor sleep was linked to increased anxiety, depression, and lower quality of life in these patients.
Effectiveness and safety of perampanel monotherapy for focal and generalized tonic-clonic seizures: Experience from a national multicenter registry.
Epilepsia
June 2020
Objective: To assess the effectiveness and tolerability of perampanel (PER) monotherapy in routine clinical practice for the treatment of focal onset and generalized tonic-clonic seizures (GTCS).
Methods: This multicenter, retrospective, observational study was conducted in patients aged ≥12 years treated with PER as primary monotherapy or converted to PER monotherapy by progressive reduction of background antiepileptic drugs. Outcomes included retention, responder, and seizure-free rate after 3, 6, and 12 months and tolerability throughout the follow-up.
Corrigendum to "Effectiveness and safety of perampanel as early add-on treatment in patients with epilepsy and focal seizures in the routine clinical practice: Spain prospective study (PERADON)" [Epilepsy Behav 102 (2020) 106655].
Epilepsy Behav
March 2020
Effectiveness and safety of perampanel as early add-on treatment in patients with epilepsy and focal seizures in the routine clinical practice: Spain prospective study (PERADON).
Epilepsy Behav
January 2020
Objective: Perampanel (PER) has been shown to be effective as an adjunctive therapy for controlling refractory focal-onset seizures (FOS). However, the information as early add-on for the treatment of FOS in the clinical practice is still scarce and must be further assessed.
Methods: An observational prospective study was conducted to evaluate the effectiveness of early add-on PER, assessed as 50% responders (seizure frequency reduced by at least 50% during the last 3 months as compared with baseline) rate at 6 and 12 months, in patients with FOS in the routine clinical practice of Spain.
Objective: Evaluate if eslicarbazepine acetate (ESL) in combination with other non-inducer antiepileptic drugs (AEDs) in the treatment of epilepsy may represent a positive impact in the cardiovascular risk profile.
Methods: multicentre, retrospective, observational, non-interventional, real-life study comparing patients treated with cytochrome P450 (CYP) inducer vs. ESL plus non-inducer AEDs.